Booting Earth Optimization System
Thank you for your patience. Your civilization is very important to us.
BEACOPP (Bleomycin, Etoposide, Doxorubicin, Cyclophosphamide, Vincristine, Procarbazine, Prednisone)
Treatment for Hodgkin lymphoma
Typical Dosage: Standardized regimen (e.g., EscBEACOPP: Bleomycin 10mg/m2, Etoposide 200mg/m2, Doxorubicin 35mg/m2, Cyclophosphamide 1250mg/m2, Vincristine 1.4mg/m2, Procarbazine 100mg/m2, Prednisone 40mg/m2)
Effectiveness
90%
Safety Score
25%
Clinical Trials
12
Participants
15K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
25
DangerousModerateSafe
Treatment Details
Dosage Range
Standardized regimen (e.g., EscBEACOPP: Bleomycin 10mg/m2, Etoposide 200mg/m2, Doxorubicin 35mg/m2, Cyclophosphamide 1250mg/m2, Vincristine 1.4mg/m2, Procarbazine 100mg/m2, Prednisone 40mg/m2)
Time to Effect
Weeks to months
Treatment Duration
4-8 months
Evidence Quality
HIGHConfidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$25,000
Monitoring:$15,000
Side Effect Mgmt:$18,000
Total Annual:$58,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
MODERATEQALYs Gained
25.8
Outcome-Based Costs
Cost per Responder
$64,444
Cost per Remission
$68,235
Comparison vs ABVD
Cost Difference
+$28,500/year
More expensive
QALY Difference
+0.80 QALYs
Better outcomes
Dominance
No dominance
BEACOPP (Bleomycin, Etoposide, Doxorubicin, Cyclophosphamide, Vincristine, Procarbazine, Prednisone) Outcomes
for Hodgkin lymphoma
WARNING: LIMITED TRIALS AVAILABLE
You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!
Active Clinical Trials
2 active trials recruiting for BEACOPP (Bleomycin, Etoposide, Doxorubicin, Cyclophosphamide, Vincristine, Procarbazine, Prednisone) in Hodgkin lymphoma
HD21 for Advanced Stages
NCT02661503ACTIVE NOT RECRUITINGPHASE3
1.5K participants
INTERVENTIONAL
Cologne, Germany
Started: Jul 1, 2016
Prognostic Significance of ctDNA in HL
NCT06263530RECRUITING
500 participants
OBSERVATIONAL
Hradec Králové, Czechia +4 more
Started: Jan 2, 2022
Completed Clinical Trials
6 completed trials for BEACOPP (Bleomycin, Etoposide, Doxorubicin, Cyclophosphamide, Vincristine, Procarbazine, Prednisone) in Hodgkin lymphoma
Study Comparing ABVD vs BEACOPP in Advanced Hodgkin's Lymphoma
NCT01251107COMPLETEDPHASE3
331 participants
INTERVENTIONAL
Milan, Italy
Started: Mar 1, 2000
Brentuximab Vedotin as Consolidation Treatment in Patients With Stage I/II HL and PET Positivity After 2 Cycles of ABVD
NCT02298283COMPLETEDPHASE2
40 participants
INTERVENTIONAL
Argenteuil, France +29 more
Started: Apr 1, 2015
Comparison of Two Combination Chemotherapy Regimens in Treating Patients With Stage III or Stage IV Hodgkin's Lymphoma
NCT00049595COMPLETEDPHASE3
552 participants
INTERVENTIONAL
Garran, Australia +139 more
Started: Aug 1, 2002
Response-Based Therapy Assessed By PET Scan in Treating Patients With Bulky Stage I and Stage II Classical Hodgkin Lymphoma
NCT01118026COMPLETEDPHASE2
101 participants
INTERVENTIONAL
San Diego, United States +54 more
Started: Sep 1, 2010
Combination Chemotherapy and Radiation Therapy in Treating Children With Previously Untreated Stage II, Stage III, or Stage IV Hodgkin's Disease
NCT00004010COMPLETEDPHASE2
99 participants
INTERVENTIONAL
Long Beach, United States +39 more
Started: Oct 1, 1999
S0816 Fludeoxyglucose F 18-PET/CT Imaging and Combination Chemotherapy With or Without Additional Chemotherapy and G-CSF in Treating Patients With Stage III or Stage IV Hodgkin Lymphoma
NCT00822120COMPLETEDPHASE2
371 participants
INTERVENTIONAL
Tucson, United States +422 more
Started: Jul 1, 2009